Two near-term data catalysts expected in 2023
Entered active collaboration with Alvogen Pharmaceuticals and Lotus Pharmaceuticals for global development and commercialization of NRX-101 in suicidal. -Today at 04:10 pm- MarketScreener
Two near-term data catalysts expected in 2023 Entered active collaboration with Alvogen Pharmaceuticals and Lotus Pharmaceuticals for global development and.
RADNOR, Pa., Aug. 7, 2023 /PRNewswire/ NRx Pharmaceuticals, Inc. , a late-stage biopharmaceutical company, today announced that it will release its second quarter 2023 financial results after.
NRx has Licensed US Patent 8,653,120 for use of D-Cycloserine to treat Chronic Pain Dr. Vania Apkarian, a world leader in pain and D-Cycloserine research, has joined the NRx Scientific Advisory.